StockMacro
Menu

Axsome Therapeutics

$129.36 -45% in 6 monthsMarket cap $6.8B

AXSM on XNAS, Health Care, Axsome Therapeutics, Inc, job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 52% to $259.7M, but shares fell 45% in six months while the 12-month loss is $157.3M.

  • BadFree cash flow was -$82.6M over 12 months, so cash went out
  • BadInstitutional holders fell to 460 from 496, down 7.3% in a quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Industry
Pharmaceutical preparations (Health Care)
Employees
925
Website
axsome.com
Listed
Nasdaq, US
Last results
2 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $259.7M, net loss $12.9M.
Quarter to 31 Dec 2021: revenue –, net income -$34.0MQuarter to 31 Mar 2022: revenue –, net income -$39.6MQuarter to 30 Jun 2022: revenue $8.8M, net income -$41.4MQuarter to 30 Jun 2022: revenue $8.8M, net income -$41.4MQuarter to 30 Sep 2022: revenue $16.8M, net income -$44.8MQuarter to 30 Sep 2022: revenue $16.8M, net income -$44.8MQuarter to 31 Dec 2022: revenue $24.4M, net income -$61.2MQuarter to 31 Dec 2022: revenue $24.4M, net income -$61.2MQuarter to 31 Mar 2023: revenue $94.6M, net income -$11.2MQuarter to 31 Mar 2023: revenue $94.6M, net income -$11.2MQuarter to 30 Jun 2023: revenue $46.7M, net income -$67.2MQuarter to 30 Jun 2023: revenue $46.7M, net income -$67.2MQuarter to 30 Sep 2023: revenue $57.8M, net income -$62.2MQuarter to 30 Sep 2023: revenue $57.8M, net income -$62.2MQuarter to 31 Dec 2023: revenue $71.5M, net income -$98.7MQuarter to 31 Dec 2023: revenue $71.5M, net income -$98.7MQuarter to 31 Mar 2024: revenue $75.0M, net income -$68.4MQuarter to 31 Mar 2024: revenue $75.0M, net income -$68.4MQuarter to 30 Jun 2024: revenue $87.2M, net income -$79.3MQuarter to 30 Jun 2024: revenue $87.2M, net income -$79.3MQuarter to 30 Sep 2024: revenue $104.8M, net income -$64.6MQuarter to 30 Sep 2024: revenue $104.8M, net income -$64.6MQuarter to 31 Dec 2024: revenue $118.8M, net income -$74.9MQuarter to 31 Dec 2024: revenue $118.8M, net income -$74.9MQuarter to 31 Mar 2025: revenue $121.5M, net income -$59.4MQuarter to 31 Mar 2025: revenue $121.5M, net income -$59.4MQuarter to 30 Jun 2025: revenue $150.0M, net income -$48.0MQuarter to 30 Jun 2025: revenue $150.0M, net income -$48.0MQuarter to 30 Sep 2025: revenue $171.0M, net income -$47.2MQuarter to 30 Sep 2025: revenue $171.0M, net income -$47.2MQuarter to 31 Dec 2025: revenue $196.0M, net income -$28.6MQuarter to 31 Dec 2025: revenue $196.0M, net income -$28.6MQuarter to 31 Mar 2026: revenue $191.2M, net income -$64.5MQuarter to 31 Mar 2026: revenue $191.2M, net income -$64.5MQuarter to 30 Jun 2026: revenue $218.4M, net income -$51.3MQuarter to 30 Jun 2026: revenue $218.4M, net income -$51.3MQuarter to 30 Sep 2026: revenue $259.7M, net income -$12.9MQuarter to 30 Sep 2026: revenue $259.7M, net income -$12.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $259.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$259.7M-$12.9M
30 Jun 2026$218.4M-$51.3M
31 Mar 2026$191.2M-$64.5M
31 Dec 2025$196.0M-$28.6M
30 Sep 2025$171.0M-$47.2M
30 Jun 2025$150.0M-$48.0M
31 Mar 2025$121.5M-$59.4M
31 Dec 2024$118.8M-$74.9M
30 Sep 2024$104.8M-$64.6M
30 Jun 2024$87.2M-$79.3M
31 Mar 2024$75.0M-$68.4M
31 Dec 2023$71.5M-$98.7M
30 Sep 2023$57.8M-$62.2M
30 Jun 2023$46.7M-$67.2M
31 Mar 2023$94.6M-$11.2M
31 Dec 2022$24.4M-$61.2M
30 Sep 2022$16.8M-$44.8M
30 Jun 2022$8.8M-$41.4M
31 Mar 2022–-$39.6M
31 Dec 2021–-$34.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $865.3M $561.3M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +54% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$157.3M -$229.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.05 -$4.67
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -17.5% -37.8% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -18.2% -40.9% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -176% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$82.6M -$101.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $313.9M $325.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $188.1M $187.6M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$125.8M (net cash) -$137.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 1.8 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.00
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 7.9 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 7.7 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 64.5 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Axsome TherapeuticsAXSM (this company) $6.8Bloss7.9+54%-18.2%
Corcept TherapeuticsCORT $6.9B42.97.2+30%16.8%
CytokineticsCYTK $7.1Bloss62.4+30%-687%
Oruka TherapeuticsORKA $6.5Bloss–––
Amneal PharmaceuticalsAMRX $7.4B55.22.3+8.9%4.2%
Kiniksa Pharmaceuticals InternationalKNSA $7.4B67.37.8+58%11.6%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$2.1M

bought $0, sold $2.1M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-7.3%

460 13F filers vs 496

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

76%

40.0M shares held by 13F filers (30 Sep 2026) of 52.6M outstanding (26 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.2%

3.3M shares sold short (30 Oct 2026) of 52.6M outstanding (26 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.4

3.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+4.9%

3.1M shares sold short in the report before, 3.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

54%

54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+52%

$259.7M vs $171.0M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

19

19 articles in the last 7 days; its usual week has 5.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.5×

19 articles in the last 7 days; its usual week has 5.5.

Price $129.36 on 20 Nov 2026, -9.7% over 12 months (12-month range $129.36 to $255.17)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $112.5M in the last 12 months (the 12 months before: -$69.0M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $259.7M in the latest quarter, +52% on a year earlier.
Capital spending per quarter. Capital spending $197K in the latest quarter, +240% on a year earlier.
Institutional holders (13F filers). 460 13F filers reported holding it in the latest 13F quarter, +36% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
9 Jun 20268-K and other filingsDirector or officer change
9 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 82 vs usual 35 (2025-03-31); 2.4x the same period a year earlier
13 May 20258-K and other filingsA major agreement ended
11 Oct 20238-K and other filingsDirector or officer change
11 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Jun 20238-K and other filingsChanged its auditor
8 Jun 20238-K and other filingsDirector or officer change
8 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Feb 2023Sharp changeMany funds opening a new position: many funds opening a new position, 53 vs usual 24.50 (2022-12-31); 3.5x the same period a year earlier
14 Nov 20228-K and other filingsCompleted an acquisition or asset sale
28 Jun 2022Sharp changeShort interest spike: short interest spike, 5.2M vs usual 3.6M (2022-06-15); 1.6x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 5.0M vs usual 3.5M (2022-05-31); 1.5x the same period a year earlier
9 May 20228-K and other filingsCompleted an acquisition or asset sale
12 Apr 2022Sharp changeShort interest spike: short interest spike, 4.8M vs usual 3.3M (2022-03-31); 1.6x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 4.5M vs usual 3.3M (2022-03-15); 1.4x the same period a year earlier
23 Nov 2021Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 198K)
Insider net buying (open market)
Month from 1 Nov 2021: $231K published
Month from 1 Sep 2023: -$2.2M published
Month from 1 Mar 2024: -$2.3M published
Month from 1 Apr 2024: -$1.9M published
Month from 1 May 2024: -$1.4M published
Month from 1 Aug 2024: -$4.0M published
Month from 1 Sep 2024: -$1.0M published
Month from 1 Feb 2025: -$2.0M published
Month from 1 May 2025: -$5.3M published
Month from 1 Jun 2025: -$6.4M published
Month from 1 Aug 2025: -$11.7M published
Month from 1 Sep 2025: -$16.4M published
Month from 1 Oct 2025: -$5.4M published
Month from 1 Nov 2025: -$21.8M published
Month from 1 Dec 2025: -$11.6M published
Month from 1 Jan 2026: -$33.7M published
Month from 1 Feb 2026: -$15.8M published
Month from 1 Apr 2026: -$1.4M published
Month from 1 May 2026: -$1.1M published
Month from 1 Jun 2026: -$24.4M published
Month from 1 Jul 2026: -$11.9M published
Month from 1 Aug 2026: -$10.5M published
Month from 1 Sep 2026: -$2.1M published
H-1B/E-3 applications certified
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Jul 2026: 1 published
Revenue per quarter
Quarter ended 30 Jun 2021: $0; public on 10 Aug 2022
Quarter ended 30 Sep 2021: $0; public on 8 Nov 2022
Quarter ended 30 Jun 2022: $8.8M; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $16.8M; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $24.4M; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $94.6M; public on 10 May 2023
Quarter ended 30 Jun 2023: $46.7M, +429% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $57.8M, +243% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $71.5M, +193% on a year earlier; public on 24 Feb 2024
Quarter ended 31 Mar 2024: $75.0M, -21% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $87.2M, +87% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $104.8M, +81% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $118.8M, +66% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $121.5M, +62% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $150.0M, +72% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $171.0M, +63% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $196.0M, +65% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $191.2M, +57% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $218.4M, +46% on a year earlier; public on 11 Aug 2026
Quarter ended 30 Sep 2026: $259.7M, +52% on a year earlier; public on 3 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $214K, +613% on a year earlier; public on 3 May 2022
Quarter ended 30 Jun 2022: $241K, +1179% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $66K; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $181K; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $71K, -67% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $133K, -45% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $371K, +462% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $7K, -96% on a year earlier; public on 24 Feb 2024
Quarter ended 31 Mar 2024: $98K, +38% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $52K, -61% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $90K, -76% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $30K, +329% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $338K, +245% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $13K, -75% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $58K, -36% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $71K, +137% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $121K, -64% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $450K, +3362% on a year earlier; public on 11 Aug 2026
Quarter ended 30 Sep 2026: $197K, +240% on a year earlier; public on 3 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 151; public on 14 Feb 2022
31 Mar 2022 report: 166; public on 16 May 2022
30 Jun 2022 report: 164; public on 15 Aug 2022
30 Sep 2022 report: 172; public on 14 Nov 2022
31 Dec 2022 report: 206; public on 14 Feb 2023
31 Mar 2023 report: 186; public on 15 May 2023
30 Jun 2023 report: 214; public on 14 Aug 2023
30 Sep 2023 report: 204; public on 14 Nov 2023
31 Dec 2023 report: 231; public on 14 Feb 2024
31 Mar 2024 report: 245; public on 15 May 2024
30 Jun 2024 report: 241; public on 14 Aug 2024
30 Sep 2024 report: 269; public on 14 Nov 2024
31 Dec 2024 report: 284; public on 14 Feb 2025
31 Mar 2025 report: 338; public on 15 May 2025
30 Jun 2025 report: 329; public on 14 Aug 2025
30 Sep 2025 report: 339; public on 14 Nov 2025
31 Dec 2025 report: 377; public on 17 Feb 2026
31 Mar 2026 report: 402; public on 15 May 2026
30 Jun 2026 report: 496; public on 14 Aug 2026
30 Sep 2026 report: 460; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $259.7M (30 Sep 2026), 1.6× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $112.5M in the last 12 months (the 12 months before: -$69.0M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $259.7M in the latest quarter, +52% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 58 insider trades

Last 90 days: 1 sale, $2.1M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
3 Sep 2026Mark L. JacobsonChief Operating OfficerSellplanned in advance (10b5-1); after exercising options10,000$208.65$2.1MForm 4
7 Aug 2026Herriot TabuteauChief Executive OfficerSellplanned in advance (10b5-1); after exercising options49,664$212.19$10.5MForm 4
1 Jul 2026Herriot TabuteauChief Executive OfficerSellplanned in advance (10b5-1); after exercising options49,666$240.25$11.9MForm 4
11 Jun 2026Roger JeffsDirectorSellplanned in advance (10b5-1)572$247.65$142KForm 4
10 Jun 2026Susan MahonyDirectorSellplanned in advance (10b5-1); after exercising options600$241.69$145KForm 4
10 Jun 2026Mark ColemanDirectorSellplanned in advance (10b5-1); after exercising options643$249.00$160KForm 4
9 Jun 2026Nick PizzieChief Financial OfficerSellplanned in advance (10b5-1); after exercising options33,000$240.09$7.9MForm 4
9 Jun 2026Herriot TabuteauChief Executive OfficerSellplanned in advance (10b5-1); after exercising options49,670$241.01$12.0MForm 4

460 institutions reported shares at the end of Q3 2026, 76% of the shares outstanding; 60 opened a position, 96 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.3.5M6.56%$636.5M+348K+11%
Vanguard Capital Management LLC2.0M3.82%$370.1M+42K+2.1%
Vanguard Portfolio Management LLC2.0M3.75%$363.7M-11K-0.5%
Invesco Ltd.1.9M3.67%$355.9M+259K+15%
FMR LLC (Fidelity)1.4M2.75%$266.3M-95K-6.2%
Millennium Management LLC1.3M2.52%$244.0M+767K+138%
Two Sigma Investments, LP1.1M2.11%$204.8M+441K+66%
Geode Capital Management, LLC1.0M1.92%$186.3M+43K+4.5%
UBS Group AG850K1.62%$156.7M+698K+459%
State Street Corp823K1.57%$151.8M+38K+4.8%

Company events

All 35 company events

In 12 months: 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Jun 2026Director or officer change8-K
13 May 2025Signed a major agreement; A major agreement endedSame filing: took on new debt, sold shares privately8-K
1 Oct 2024Signed a major agreement8-K
11 Oct 2023Director or officer change8-K
26 Jun 2023Changed its auditor8-K
8 Jun 2023Director or officer changeSame filing: shareholder vote results8-K
22 Feb 2023Signed a major agreement8-K
9 Jan 2023Signed a major agreement8-K

The 5 newest of 291 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

21 May 2019confirmed

Confirmed across sources Insiders and Institutional holdings and Short interest and volume

Axsome Therapeutics (AXSM): saw 36 13F filers open a new position in the quarter ended 31 Mar 2019, 3.6× the same quarter last year; it also had 3 insiders buy $218K of its shares on the open market within 30 days (3 filings); and it had 6.2M shares sold short in the 31 May 2019 report, 8.2× the same report last year. Three unrelated kinds of activity within 63 days.

  • Short interest and volume: Short interest spike, became public on 26 Apr 2019
  • Short interest and volume: Short interest spike, became public on 10 May 2019
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2019
  • Short interest and volume: Short interest spike, became public on 25 May 2019
  • Insiders: Clustered insider buying, became public on 13 Jun 2019
  • Short interest and volume: Short interest spike, became public on 12 Jun 2019
  • Short interest and volume: Short interest spike, became public on 26 Jun 2019
2017-03-31: 112017-06-30: 52017-09-30: 52017-12-31: 82018-03-31: 102018-06-30: 32018-09-30: 62018-12-31: 112019-03-31: 36
The quarter ended 31 Mar 2019 against the 8 quarters before it. this quarterearliernormal: 7
See the evidence (7 changes)

Short interest and volume: Short interest spike became public on 26 Apr 2019

Axsome Therapeutics had 5.3M shares sold short in the 15 Apr 2019 report, 9.3× the same report last year.

This period
5.3M (the 15 Apr 2019 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
534K
How far from its usual level
+4.9
Same report last year
565K
History used
472 days
2018-04-13: 565K2018-04-30: 622K2018-05-15: 715K2018-05-31: 754K2018-06-15: 888K2018-06-29: 1.8M2018-07-13: 1.8M2018-07-31: 1.6M2018-08-15: 1.5M2018-08-31: 1.4M2018-09-14: 1.4M2018-09-28: 1.5M2018-10-15: 884K2018-10-31: 1.2M2018-11-15: 879K2018-11-30: 1.1M2018-12-14: 892K2018-12-31: 1.1M2019-01-15: 1.8M2019-01-31: 2.1M2019-02-15: 2.9M2019-02-28: 2.9M2019-03-15: 3.8M2019-03-29: 5.1M2019-04-15: 5.3M
the 15 Apr 2019 report24 earlier reportsnormal: 1.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 May 2019

Axsome Therapeutics had 5.0M shares sold short in the 30 Apr 2019 report, 8.1× the same report last year.

This period
5.0M (the 30 Apr 2019 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
566K
How far from its usual level
+4.3
Same report last year
622K
History used
487 days
2018-04-30: 622K2018-05-15: 715K2018-05-31: 754K2018-06-15: 888K2018-06-29: 1.8M2018-07-13: 1.8M2018-07-31: 1.6M2018-08-15: 1.5M2018-08-31: 1.4M2018-09-14: 1.4M2018-09-28: 1.5M2018-10-15: 884K2018-10-31: 1.2M2018-11-15: 879K2018-11-30: 1.1M2018-12-14: 892K2018-12-31: 1.1M2019-01-15: 1.8M2019-01-31: 2.1M2019-02-15: 2.9M2019-02-28: 2.9M2019-03-15: 3.8M2019-03-29: 5.1M2019-04-15: 5.3M2019-04-30: 5.0M
the 30 Apr 2019 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2019

Axsome Therapeutics saw 36 13F filers open a new position in the quarter ended 31 Mar 2019, 3.6× the same quarter last year.

This period
36 (the quarter ended 31 Mar 2019)
Normal quarter (median of 8 earlier)
7
Typical spread (median absolute deviation)
2.5
How far from its usual level
+7.8
Same quarter last year
10
History used
1,186 days
2017-03-31: 112017-06-30: 52017-09-30: 52017-12-31: 82018-03-31: 102018-06-30: 32018-09-30: 62018-12-31: 112019-03-31: 36
the quarter ended 31 Mar 20198 earlier quartersnormal: 7

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 25 May 2019

Axsome Therapeutics had 5.7M shares sold short in the 15 May 2019 report, 7.9× the same report last year.

This period
5.7M (the 15 May 2019 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
587K
How far from its usual level
+4.8
Same report last year
715K
History used
502 days
2018-05-15: 715K2018-05-31: 754K2018-06-15: 888K2018-06-29: 1.8M2018-07-13: 1.8M2018-07-31: 1.6M2018-08-15: 1.5M2018-08-31: 1.4M2018-09-14: 1.4M2018-09-28: 1.5M2018-10-15: 884K2018-10-31: 1.2M2018-11-15: 879K2018-11-30: 1.1M2018-12-14: 892K2018-12-31: 1.1M2019-01-15: 1.8M2019-01-31: 2.1M2019-02-15: 2.9M2019-02-28: 2.9M2019-03-15: 3.8M2019-03-29: 5.1M2019-04-15: 5.3M2019-04-30: 5.0M2019-05-15: 5.7M
the 15 May 2019 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Insiders: Clustered insider buying became public on 13 Jun 2019

Axsome Therapeutics had 3 insiders buy $218K of its shares on the open market within 30 days (3 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$218K
Window
14 May 2019 to 13 Jun 2019

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 12 Jun 2019

Axsome Therapeutics had 6.2M shares sold short in the 31 May 2019 report, 8.2× the same report last year.

This period
6.2M (the 31 May 2019 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
587K
How far from its usual level
+5.3
Same report last year
754K
History used
518 days
2018-05-31: 754K2018-06-15: 888K2018-06-29: 1.8M2018-07-13: 1.8M2018-07-31: 1.6M2018-08-15: 1.5M2018-08-31: 1.4M2018-09-14: 1.4M2018-09-28: 1.5M2018-10-15: 884K2018-10-31: 1.2M2018-11-15: 879K2018-11-30: 1.1M2018-12-14: 892K2018-12-31: 1.1M2019-01-15: 1.8M2019-01-31: 2.1M2019-02-15: 2.9M2019-02-28: 2.9M2019-03-15: 3.8M2019-03-29: 5.1M2019-04-15: 5.3M2019-04-30: 5.0M2019-05-15: 5.7M2019-05-31: 6.2M
the 31 May 2019 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jun 2019

Axsome Therapeutics had 5.7M shares sold short in the 14 Jun 2019 report, 6.5× the same report last year.

This period
5.7M (the 14 Jun 2019 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
698K
How far from its usual level
+3.9
Same report last year
888K
History used
532 days
2018-06-15: 888K2018-06-29: 1.8M2018-07-13: 1.8M2018-07-31: 1.6M2018-08-15: 1.5M2018-08-31: 1.4M2018-09-14: 1.4M2018-09-28: 1.5M2018-10-15: 884K2018-10-31: 1.2M2018-11-15: 879K2018-11-30: 1.1M2018-12-14: 892K2018-12-31: 1.1M2019-01-15: 1.8M2019-01-31: 2.1M2019-02-15: 2.9M2019-02-28: 2.9M2019-03-15: 3.8M2019-03-29: 5.1M2019-04-15: 5.3M2019-04-30: 5.0M2019-05-15: 5.7M2019-05-31: 6.2M2019-06-14: 5.7M
the 14 Jun 2019 report24 earlier reportsnormal: 1.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 9 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 9 Jun 2026Filings record

    Director or officer change

  3. 10 Sep 2025Insiders record

    Coleman Mark (director) bought 1,575 shares of AXSM ($200,466) (dated 9 Sep 2025)

  4. 15 May 2025Institutional holdings change

    saw 82 13F filers open a new position in the quarter ended 31 Mar 2025, 2.4× the same quarter last year.

    Same quarter last year: 34; its normal quarter is 35.

    See the evidence
    This period
    82 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    35
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +4.9
    Same quarter last year
    34
    History used
    3,378 days
    2023-03-31: 182023-06-30: 432023-09-30: 192023-12-31: 362024-03-31: 342024-06-30: 302024-09-30: 402024-12-31: 492025-03-31: 82
    the quarter ended 31 Mar 20258 earlier quartersnormal: 35

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  5. 13 May 2025Filings record

    A major agreement ended

  6. 11 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 11 Oct 2023Filings record

    Director or officer change

  8. 26 Jun 2023Filings record

    Changed its auditor

  9. 8 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 8 Jun 2023Filings record

    Director or officer change

  11. 14 Feb 2023Institutional holdings change

    saw 53 13F filers open a new position in the quarter ended 31 Dec 2022, 3.5× the same quarter last year.

    Same quarter last year: 15; its normal quarter is 24.5.

    See the evidence
    This period
    53 (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    24.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +6.4
    Same quarter last year
    15
    History used
    2,557 days
    2020-12-31: 152021-03-31: 272021-06-30: 222021-09-30: 282021-12-31: 152022-03-31: 262022-06-30: 232022-09-30: 382022-12-31: 53
    the quarter ended 31 Dec 20228 earlier quartersnormal: 24.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  12. 14 Nov 2022Filings record

    Completed an acquisition or asset sale

  13. 28 Jun 2022Short interest and volume change

    had 5.2M shares sold short in the 15 Jun 2022 report, 1.6× the same report last year.

    Same report last year: 3.3M; its normal report is 3.6M.

    See the evidence
    This period
    5.2M (the 15 Jun 2022 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    264K
    How far from its usual level
    +4.3
    Same report last year
    3.3M
    History used
    1,629 days
    2021-05-28: 3.4M2021-06-15: 3.3M2021-06-30: 2.9M2021-07-15: 2.7M2021-07-30: 2.9M2021-08-13: 3.4M2021-08-31: 4.0M2021-09-15: 3.4M2021-09-30: 3.8M2021-10-15: 3.8M2021-10-29: 3.3M2021-11-15: 3.3M2021-11-30: 3.5M2021-12-15: 3.6M2022-01-14: 3.3M2022-01-31: 3.5M2022-02-15: 3.8M2022-02-28: 4.4M2022-03-15: 4.5M2022-03-31: 4.8M2022-04-14: 4.6M2022-04-29: 4.5M2022-05-13: 4.9M2022-05-31: 5.0M2022-06-15: 5.2M
    the 15 Jun 2022 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 10 Jun 2022Short interest and volume change

    had 5.0M shares sold short in the 31 May 2022 report, 1.5× the same report last year.

    Same report last year: 3.4M; its normal report is 3.5M.

    See the evidence
    This period
    5.0M (the 31 May 2022 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    277K
    How far from its usual level
    +3.7
    Same report last year
    3.4M
    History used
    1,614 days
    2021-05-14: 3.3M2021-05-28: 3.4M2021-06-15: 3.3M2021-06-30: 2.9M2021-07-15: 2.7M2021-07-30: 2.9M2021-08-13: 3.4M2021-08-31: 4.0M2021-09-15: 3.4M2021-09-30: 3.8M2021-10-15: 3.8M2021-10-29: 3.3M2021-11-15: 3.3M2021-11-30: 3.5M2021-12-15: 3.6M2022-01-14: 3.3M2022-01-31: 3.5M2022-02-15: 3.8M2022-02-28: 4.4M2022-03-15: 4.5M2022-03-31: 4.8M2022-04-14: 4.6M2022-04-29: 4.5M2022-05-13: 4.9M2022-05-31: 5.0M
    the 31 May 2022 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 9 May 2022Filings record

    Completed an acquisition or asset sale

  16. 12 Apr 2022Short interest and volume change

    had 4.8M shares sold short in the 31 Mar 2022 report, 1.6× the same report last year.

    Same report last year: 2.9M; its normal report is 3.3M.

    See the evidence
    This period
    4.8M (the 31 Mar 2022 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    252K
    How far from its usual level
    +3.8
    Same report last year
    2.9M
    History used
    1,553 days
    2021-03-15: 3.2M2021-03-31: 2.9M2021-04-15: 2.9M2021-04-30: 3.1M2021-05-14: 3.3M2021-05-28: 3.4M2021-06-15: 3.3M2021-06-30: 2.9M2021-07-15: 2.7M2021-07-30: 2.9M2021-08-13: 3.4M2021-08-31: 4.0M2021-09-15: 3.4M2021-09-30: 3.8M2021-10-15: 3.8M2021-10-29: 3.3M2021-11-15: 3.3M2021-11-30: 3.5M2021-12-15: 3.6M2022-01-14: 3.3M2022-01-31: 3.5M2022-02-15: 3.8M2022-02-28: 4.4M2022-03-15: 4.5M2022-03-31: 4.8M
    the 31 Mar 2022 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 25 Mar 2022Short interest and volume change

    had 4.5M shares sold short in the 15 Mar 2022 report, 1.4× the same report last year.

    Same report last year: 3.2M; its normal report is 3.3M.

    See the evidence
    This period
    4.5M (the 15 Mar 2022 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    201K
    How far from its usual level
    +3.5
    Same report last year
    3.2M
    History used
    1,537 days
    2021-02-26: 3.2M2021-03-15: 3.2M2021-03-31: 2.9M2021-04-15: 2.9M2021-04-30: 3.1M2021-05-14: 3.3M2021-05-28: 3.4M2021-06-15: 3.3M2021-06-30: 2.9M2021-07-15: 2.7M2021-07-30: 2.9M2021-08-13: 3.4M2021-08-31: 4.0M2021-09-15: 3.4M2021-09-30: 3.8M2021-10-15: 3.8M2021-10-29: 3.3M2021-11-15: 3.3M2021-11-30: 3.5M2021-12-15: 3.6M2022-01-14: 3.3M2022-01-31: 3.5M2022-02-15: 3.8M2022-02-28: 4.4M2022-03-15: 4.5M
    the 15 Mar 2022 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 24 Nov 2021Insiders record

    JEFFS ROGER (director) bought 3,950 shares of AXSM ($147,335) (dated 23 Nov 2021)

  19. 23 Nov 2021Insiders change

    had 3 insiders buy $198K of its shares on the open market within 30 days (3 filings).

    Who bought: Saad Mark E, Pizzie Nick, Coleman Mark.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $198K
    Window
    24 Oct 2021 to 23 Nov 2021

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  20. 23 Nov 2021Insiders record

    Coleman Mark (director) bought 1,430 shares of AXSM ($50,181) (dated 22 Nov 2021)

  21. 23 Nov 2021Insiders record

    Pizzie Nick (CHIEF FINANCIAL OFFICER) bought 955 shares of AXSM ($33,676) (dated 22 Nov 2021)

  22. 20 Nov 2021Insiders record

    Saad Mark E (director) bought 3,300 shares of AXSM ($113,915) (dated 19 Nov 2021)

  23. 14 May 2021Insiders record

    Coleman Mark (director) bought 500 shares of AXSM ($29,075) (dated 13 May 2021)

  24. 29 Sep 2020Filings record

    A major agreement ended

  25. 8 Sep 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 8 Sep 2020Filings record

    Director or officer change

  27. 1 Jul 2020Insiders record

    Pizzie Nick (Chief Financial Officer) bought 777 shares of AXSM ($59,549) (dated 30 Jun 2020)

  28. 1 Jul 2020Insiders record

    Coleman Mark (director) bought 650 shares of AXSM ($51,025) (dated 30 Jun 2020)

  29. 5 Jun 2020Filings record

    Director or officer change

  30. 21 Apr 2020Filings record

    Director or officer change

  31. 5 Mar 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 5 Mar 2020Filings record

    Director or officer change

  33. 14 Feb 2020Institutional holdings change

    saw 56 13F filers open a new position in the quarter ended 31 Dec 2019, 5.1× the same quarter last year.

    Same quarter last year: 11; its normal quarter is 10.5.

    See the evidence
    This period
    56 (the quarter ended 31 Dec 2019)
    Normal quarter (median of 8 earlier)
    10.5
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +5.1
    Same quarter last year
    11
    History used
    1,461 days
    2017-12-31: 82018-03-31: 102018-06-30: 32018-09-30: 62018-12-31: 112019-03-31: 362019-06-30: 472019-09-30: 212019-12-31: 56
    the quarter ended 31 Dec 20198 earlier quartersnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  34. 1 Oct 2019Insiders record

    Pizzie Nick (Chief Financial Officer) bought 2,180 shares of AXSM ($54,064) (dated 30 Sep 2019)

  35. 14 Aug 2019Institutional holdings change

    saw 47 13F filers open a new position in the quarter ended 30 Jun 2019, 16× the same quarter last year.

    Same quarter last year: 3; its normal quarter is 7.

    See the evidence
    This period
    47 (the quarter ended 30 Jun 2019)
    Normal quarter (median of 8 earlier)
    7
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +10.8
    Same quarter last year
    3
    History used
    1,277 days
    2017-06-30: 52017-09-30: 52017-12-31: 82018-03-31: 102018-06-30: 32018-09-30: 62018-12-31: 112019-03-31: 362019-06-30: 47
    the quarter ended 30 Jun 20198 earlier quartersnormal: 7

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  36. 28 Jun 2019Insiders record

    Coleman Mark (director) bought 16,200 shares of AXSM ($374,280) (dated 27 Jun 2019)

  37. 26 Jun 2019Short interest and volume change

    had 5.7M shares sold short in the 14 Jun 2019 report, 6.5× the same report last year.

    Same report last year: 888K; its normal report is 1.7M.

    See the evidence
    This period
    5.7M (the 14 Jun 2019 report)
    Normal report (median of 24 earlier)
    1.7M
    Typical spread (median absolute deviation)
    698K
    How far from its usual level
    +3.9
    Same report last year
    888K
    History used
    532 days
    2018-06-15: 888K2018-06-29: 1.8M2018-07-13: 1.8M2018-07-31: 1.6M2018-08-15: 1.5M2018-08-31: 1.4M2018-09-14: 1.4M2018-09-28: 1.5M2018-10-15: 884K2018-10-31: 1.2M2018-11-15: 879K2018-11-30: 1.1M2018-12-14: 892K2018-12-31: 1.1M2019-01-15: 1.8M2019-01-31: 2.1M2019-02-15: 2.9M2019-02-28: 2.9M2019-03-15: 3.8M2019-03-29: 5.1M2019-04-15: 5.3M2019-04-30: 5.0M2019-05-15: 5.7M2019-05-31: 6.2M2019-06-14: 5.7M
    the 14 Jun 2019 report24 earlier reportsnormal: 1.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 13 Jun 2019Insiders change

    had 3 insiders buy $218K of its shares on the open market within 30 days (3 filings).

    Who bought: Coleman Mark, Saad Mark E, Pizzie Nick.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $218K
    Window
    14 May 2019 to 13 Jun 2019

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  39. 13 Jun 2019Insiders record

    Pizzie Nick (Chief Financial Officer) bought 1,920 shares of AXSM ($39,936) (dated 12 Jun 2019)

  40. 12 Jun 2019Short interest and volume change

    had 6.2M shares sold short in the 31 May 2019 report, 8.2× the same report last year.

    Same report last year: 754K; its normal report is 1.5M.

    See the evidence
    This period
    6.2M (the 31 May 2019 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    587K
    How far from its usual level
    +5.3
    Same report last year
    754K
    History used
    518 days
    2018-05-31: 754K2018-06-15: 888K2018-06-29: 1.8M2018-07-13: 1.8M2018-07-31: 1.6M2018-08-15: 1.5M2018-08-31: 1.4M2018-09-14: 1.4M2018-09-28: 1.5M2018-10-15: 884K2018-10-31: 1.2M2018-11-15: 879K2018-11-30: 1.1M2018-12-14: 892K2018-12-31: 1.1M2019-01-15: 1.8M2019-01-31: 2.1M2019-02-15: 2.9M2019-02-28: 2.9M2019-03-15: 3.8M2019-03-29: 5.1M2019-04-15: 5.3M2019-04-30: 5.0M2019-05-15: 5.7M2019-05-31: 6.2M
    the 31 May 2019 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 61 entries; narrow the window or the kind of data to see older ones.

Not listed: 324 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001579428
Ticker
AXSM
Domain
axsome.com
Employer name
Axsome Therapeutics Inc. (1 unverified)
Fein
45-4241907 (1 unverified)
Hq location
NY|NEW YORK|10007 (1 unverified)
Name
Axsome Canada, Inc, Axsome International Holdings LLC, Axsome Malta Holdings Ltd, Axsome Malta Ltd and 1 more
Uei
KGMGGVWRZRW4
Wikidata
Q104480012
  • DOL H-1B labor condition applications and PERM certifications15 data points18 Mar 2024 to 4 May 2026
  • SEC Form 13F institutional holdings396 data points31 Dec 2015 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)299 records22 Mar 2016 to 2 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)657 data points31 Dec 2013 to 26 Oct 2026
  • SEC Form 4 insider transactions58 records, 200 data points20 Jun 2018 to 3 Sep 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026